Jubilant Pharmova

May 22 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• MARCH-QUARTER CONSOL NET PROFIT 1.19 BILLION RUPEES

• DECLARES DIVIDEND OF 5 RUPEES PER SHARE

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 22.90 BILLION RUPEES

Source text: [ID:]

Further company coverage: JUBA.NS

(([email protected];))

Feb 6 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• DEC-QUARTER CONSOL NET PROFIT 559 MILLION RUPEES

• DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 21.23 BILLION RUPEES

Source text: [ID:]

Further company coverage: JUBA.NS

(([email protected];))

Dec 31 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• RECEIVES TAX DEMAND ORDER FOR 221 MILLION RUPEES

Source text: ID:nBSE96N8vw

Further company coverage: JUBA.NS

(([email protected];))

July 29 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA JUNE-QUARTER CONSOL NET PROFIT 1.03 BILLION RUPEES

• JUBILANT PHARMOVA JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 18.79 BILLION RUPEES

Further company coverage: JUBA.NS

(([email protected];))

May 16 (Reuters) - India's Jubilant Pharmova JUBA.NS reported a surge in its fourth-quarter adjusted profit on Friday, driven by strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases.

The drugmaker's consolidated profit before exceptional items and taxes rose 82% year-on-year to 2.09 billion rupees ($24.4 million) in the quarter ended March 31.

Its net profit was 1.54 billion rupees in the quarter, compared with a year-ago loss of 586 million rupees, which included a 1.69-billion-rupee impairment charge for closing a plant in the U.S.

Revenue rose 10% year-over-year to 19.29 billion rupees, lifted by a 9.5% jump in revenue from the radiopharma segment, which accounted for nearly 46% of the total revenue.

The drugmaker, which makes and supplies radiopharmaceuticals used to diagnose and treat cancer and other diseases such as hyperthyroidism and lung diseases, has a network of 52 radio-pharmacies in the United States.

This field is highly regulated and complex, thus limiting competition and benefiting companies such as Jubilant Pharmova, analysts said.

Revenue from contract manufacturing, the company's second-biggest segment that makes sterile injectables, also jumped 33%. Revenue from its generics business, however, fell 22%.

($1 = 85.5930 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]; 8800437922;))

March 20 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA -JUBILANT BIOSYS SUBSCRIBES TO 80% EQUITY CAPITAL IN JASMIN

• JUBILANT PHARMOVA - JASMIN ACQUIRES PF'S RESEARCH AND DEVELOPMENT CENTRE AT SAINT JULIEN, FRANCE

Source text: ID:nBSELLpWh

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS jump 2% to 882.30 rupees

** U.S. FDA completes inspection of drugmaker's manufacturing site in Maryland, classifies it as "voluntary action indicated"

** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the FDA website

** Stock down 21% this year after doubling in 2024

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

March 12 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - JUBILANT CADISTA FACILITY RECEIVES EIR WITH VAI STATUS FROM USFDA

• JUBILANT PHARMOVA LTD - INSPECTION SUCCESSFULLY CLOSED WITH EIR RECEIPT FROM USFDA

Source text: ID:nBSE6bCy94

Further company coverage: JUBA.NS

(([email protected];))

Jan 31 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA Q3 CONSOL NET PROFIT 1.01 BILLION RUPEES

• JUBILANT PHARMOVA Q3 CONSOL INCOME FROM OPERATIONS 18.14 BILLION RUPEES

Source text: ID:nnAPN2LULWB

Further company coverage: JUBA.NS

(([email protected];;))

Jan 24 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• UNIT VOLUNTARY PREPAYS $25 MILLION TERM LOAN

Source text: ID:nBSEbSzP5v

Further company coverage: JUBA.NS

(([email protected];;))

Oct 29 (Reuters) - Ion Beam Applications SA IBAB.BR:

• PARTNERS WITH JUBILANT RADIOPHARMA, SELLING FIVE CYCLONE KIUBE

• SIGNING OF CONTRACT FOR INSTALLATION OF FIVE CYCLONE KIUBE 180 CYCLOTRONS AND ASSOCIATED EQUIPMENT IN U.S

Source text: https://shorturl.at/uAFNy

Further company coverage: IBAB.BR

(Gdansk Newsroom)

(([email protected]; +48 58 769 66 00;))

Oct 25 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• Q2 CONSOL NET PROFIT 1.03 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 17.52 BILLION RUPEES

Source text for Eikon: ID:nBSEbKP27x

Further company coverage: JUBA.NS

(([email protected];;))

Oct 10 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA- UNIT’S RECTIFICATION APPLICATION LED TO DELETION OF 381.3 MILLION RUPEES TAX DEMAND

Source text for Eikon: ID:nBSE8gg2C6

Further company coverage: JUBA.NS

(([email protected];))

Oct 4 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JBIRSPL TO ACQUIRE 80% EQUITY CAPITAL IN JASMIN FOR UPTO 4.4 MILLION EURO

• JASMIN TO ACQUIRE PIERRE FABRE’S RESEARCH AND DEVELOPMENT CENTRE AT SAINT JULIEN, FRANCE

Source text for Eikon: ID:nNSE76LCtq

Further company coverage: JUBA.NS

(([email protected];;))

Sept 26 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - COMPLETION OF USFDA AUDIT OF ALLERGY IMMUNOTHERAPY FACILITY, SPOKANE

• JUBILANT PHARMOVA - INSPECTION CONCLUDED WITH NO OBSERVATIONS

• JUBILANT PHARMOVA - COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY LOCATED AT SPOKANE

Source text for Eikon: ID:nBSEgl7Z3

Further company coverage: JUBA.NS

(([email protected];;))

** Shares of Jubilant Pharmova JUBA.NS rise as much as 4.1%, last up 1.2% to 1,030 rupees

** Co says U.S. FDA's inspection of its U.S. contract manufacturing facility classified as "Voluntary Action Indicated"

** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the U.S. FDA website

** Stock on track to rise in six out of seven straight sessions if trend holds

** JUBA up 89% YTD

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Sept 10 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - USFDA INSPECTION CLASSIFICATION OF UNIT'S FACILITY AS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE5S1Wvd

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS climb ~5% to 899 rupees, their highest since May 2021

** Drugmaker's subsidiary issues "put option offer" to Pierre Fabre Laboratories to acquire 80% stake in a new company for 4.4 mln euros ($5 mln) to be incorporated in France

**Says, new co will buy Pierre Fabre's R&D centre

** Pierre Fabre will hire services from co's Jubilant Biosys unit up to 7 mln euros for first four years

** JUBA up ~65% YTD vs ~46% last year

($1 = 0.9054 euros)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Aug 16 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - UNIT SIGNED, ISSUED "PUT OPTION OFFER" TO PIERRE FABRE LABORATORIES

• JUBILANT PHARMOVA - OFFER TO ACQUIRE 80% CAPITAL IN NEW CO TO BE INCORPORATED IN FRANCE

• JUBILANT PHARMOVA - UNIT TO INVEST UPTO EURO 14.4 MILLION IN 7 YEARS

Source text for Eikon: ID:nNSE4WJsVk

Further company coverage: JUBA.NS

(([email protected];))

BENGALURU, July 19 (Reuters) - Indian pharmaceutical firm Jubilant Pharmova JUBA.NS reported a nearly four-fold rise in first-quarter adjusted profit on Friday, boosted by strong demand for its drugs that contain radioactive ingredients.

The company's consolidated net profit before exceptional items and taxes rose to 1.04 billion rupees ($12.4 million) in the three months ended June 30 from 252 million rupees a year earlier.

The company had a one-time gain of 3.96 billion rupees after the sale of one of its units in the United States.

The company's shares rose as much as 10% after the results to a three-year high of 800 rupees, before paring most of the gains.

Analysts expect consistent growth in the company's high-margin radiopharma segment to drive revenue growth.

Jubilant Pharmova is involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the United States. The company said it will invest $50 million to add six sites in its radiopharmacy network.

Total revenue rose 9% to 17.32 billion rupees, lifted by a 20.5% rise in the radiopharma segment. The business, which involves developing radioactive medications used to diagnose or treat cancer, accounted for more than 48% of the total revenue.

Revenue from its contract manufacturing segment, its second-biggest, also climbed 13% to 3.34 billion rupees.

($1 = 83.6250 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Subhranshu Sahu and Sohini Goswami)

(([email protected]; 8800437922;))

June 18 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - ANNOUNCES COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY AT MONTREAL, CANADA

• JUBILANT PHARMOVA LTD - USFDA HAS ISSUED 15 OBSERVATIONS PURSUANT TO COMPLETION OF AUDIT

• JUBILANT PHARMOVA - JHSGP WILL SUBMIT AN ACTION PLAN ON OBSERVATIONS

Source text for Eikon: ID:nBSE8PMrCL

Further company coverage: JUBA.NS

(([email protected];))

June 14 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• UNIT ANNOUNCED AN INVESTMENT OF $50 MILLION TO EXPAND ITS PET RADIOPHARMACY NETWORK

• ADDING SIX PET RADIOPHARMACIES IN STRATEGIC LOCATIONS THROUGHOUT UNITED STATES

• INVESTMENT WILL EXPAND CO'S PET RADIOPHARMACY NETWORK TO NINE SITES, OVERALL RADIOPHARMACY NETWORK TO FIFTY TWO SITES

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS fall as much as 3.3% to 732.35 rupees; last down 1.7%

** The pharmaceuticals company said on Friday that the U.S. Food and Drug Administration (USFDA) closed an inspection at its contract manufacturing facility in Washington with three observations

** More than 271,000 shares traded by 02:30 p.m. IST, 0.8x times their 30-day avg

** JUBA on track to snap three straight sessions of gains, if current trends hold

** Including session's move, stock is up 36.4% YTD

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

June 7 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - ANNOUNCES COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON

• JUBILANT PHARMOVA LTD - USFDA HAS ISSUED 3 OBSERVATIONS PURSUANT TO COMPLETION OF AUDIT

• JUBILANT PHARMOVA LTD - COMPANY WILL SUBMIT AN ACTION PLAN ON OBSERVATIONS

Source text for Eikon: ID:nBSE210hpx

Further company coverage: JUBA.NS

(([email protected];))

BENGALURU, May 29 (Reuters) - Indian pharmaceutical firm Jubilant Pharmova JUBA.NS reported a narrower fourth-quarter loss on Wednesday, aided by strong demand for drugs that contain radioactive ingredients.

The company's consolidated net loss narrowed to 586 million rupees ($7 million) in the January to March period, compared with a loss of 979 million rupees a year ago.

Jubilant Pharmova, involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the U.S., said it is on track to launch new products in this segment in the medium-term.

Sales rose 5% to 17.46 billion rupees in the fourth quarter, lifted by an 18.6% rise in the key radiopharma business, which involves developing medications used to diagnose or treat diseases such as cancer, and made up nearly half of the sales.

Revenue from segments that make copycat drugs and medicines used for allergy immunotherapy rose 0.8% and 14%, respectively, during the quarter.

The drugmaking arm of the polymers-to-pizza Jubilant Bhartia group declared a dividend of 5 rupees per share.

Its shares ended 0.4% higher after results and are up 29.5% so far this year.

($1 = 83.3335 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected]; X: @MukherjeeHritam;))

May 28 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - APPROVED INVESTMENT INCLUDING ENTERING INTO POWER SUPPLY AND OFFTAKE AGREEMENT WITH ISHARAYS ENERGY TWO

• JUBILANT PHARMOVA LTD - UNIT'S ACQUISITION CONSIDERATION 30.9 MILLION RUPEES

• JUBILANT PHARMOVA LTD -UNIT APPROVED ENTERING INTO SHARE SUBSCRIPTION AND SHAREHOLDERS AGREEMENT WITH ISHARAYS ENERGY TWO PRIVATE

Source text for Eikon: ID:nBSE8zM0jp

Further company coverage: JUBA.NS

(([email protected];))

April 30 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - TAX DEMAND OF 1.9 BILLION RUPEES STANDS DELETED IN ITS ENTIRETY

Source text for Eikon: ID:nBSE2jJ9hY

Further company coverage: JUBA.NS

(([email protected];))

** Shares of pharma company Jubilant Pharmova JUBA.NS rise as much as 5.7% to 710 rupees, their highest level since July 26, 2021

** Stock eyes a third straight session of gains

** U.S. regulator Food and Drug Administration classifies JUBA's Roorkee facility to manufacture solid dosage as Voluntary Action Indicated (VAI)

** VAI implies the facility is in compliance with good manufacturing practices

** Following the VAI status to Roorkee plant, JUBA says "it expects exports from the facility to U.S. market to increase in a meaningful manner"

** "These actions are expected to improve the gross margins of the generics business by reducing manufacturing, quality management and overhead costs," JUBA says in an exchange filing

** More than 700,000 shares change hands, about 1.6x the 30-day avg

** Stock up 20.7% so far YTD

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

April 17 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• USFDA DETERMINES INSPECTION CLASSIFICATION OF 'VOLUNTARY ACTION INDICATED' FOR SOLID DOSAGE MANUFACTURING FACILITY AT ROORKEE

• FACILITY IS CONSIDERED TO BE IN ACCEPTABLE STATE OF COMPLIANCE WITH REGARD TO CURRENT GOOD MANUFACTURING PRACTICES

Source text for Eikon: ID:nBSE4MK70w

Further company coverage: JUBA.NS

(([email protected];))

BENGALURU, Feb 2 (Reuters) - Indian pharmaceutical firm Jubilant Pharmova JUBA.NS on Friday reported a third-quarter profit, compared to a loss a year earlier, on strong demand for its radiopharma business.

The company posted a net profit of 668 million rupees ($8.06 million) for the quarter ended Dec. 31, compared to a loss of 156 million rupees a year ago.

The Noida-based firm's total revenue rose 8% to 16.77 billion rupees, with its radiopharma business - which involves developing radioactive medications used to diagnose or treat cancer - making up more than 40% of the total. The segment grew 22.7% during the quarter.

This is the fifth straight quarter that the company's revenue has risen.

Jubilant Pharmova is involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the U.S.

The company's future revenue will be driven by its high-margin radiopharmaceuticals division, according to analysts.

Shares of Jubilant Pharmova rose as much as 7% after the results, hitting a more than two-year high.

($1 = 82.8630 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +91 7982114624;))